# Fair Underwriting - Investor Pitch Deck

**Last Updated**: November 7, 2025
**Purpose**: Series A fundraising presentation ($10-15M target)
**Audience**: Healthcare VCs, impact investors, biotech/digital health funds
**Format**: 15-20 slide deck (10-min pitch + 10-min Q&A)

---

## Slide-by-Slide Content

### Slide 1: Cover

**Visual**: Fair Underwriting logo + tagline

**Text**:

```
Fair Underwriting
Genetic Wellness for Everyone

Transforming genetic testing from risk assessment tool
to health empowerment platform

Series A | $10-15M
```

**Speaker Notes**:

- Opening hook: "1 in 25 Americans carries a genetic mutation that increases COPD risk 2-4x, but 98% don't know it. We're changing that."
- Introduce yourself: Name, title, 30-second background
- Set context: "Today I'll show you how Fair Underwriting is building the future of preventive genetic testingâ€”privacy-protected, insurance-partnered, and proven to save lives and lower healthcare costs."

---

### Slide 2: The Problem

**Visual**: Split-screen showing anxious customer + stack of bills

**Headline**: **Genetic Testing is Broken**

**3 Key Problems** (bullet points with icons):

1. **Fear of Discrimination** ðŸ”’
   - 72% of Americans worried genetic test results will be used against them by insurers
   - GINA protections exist but public doesn't trust them
   - Result: Only 4% of eligible people get genetic testing

2. **Diagnostic Gaps Kill** ðŸ’”
   - Alpha-1 Antitrypsin Deficiency (AATD): 100,000+ Americans affected, 90% undiagnosed
   - MZ carriers (1 in 25): 2-4x COPD risk, but rarely tested until symptomatic
   - Late diagnosis = irreversible lung/liver damage

3. **Insurers Miss Prevention Opportunity** ðŸ’°
   - COPD costs insurers $5,000-15,000/year per patient
   - Early detection + smoking cessation = 58% risk reduction
   - Insurers don't screen because they can't access results without violating privacy â†’ **catch-22**

**Speaker Notes**:

- "Genetic testing should be the ultimate preventive care toolâ€”catch disease risk before symptoms, intervene early, save lives and money. But it's not working."
- "The root cause? Privacy fears. People are terrified their insurer will see their results and discriminate against them."
- "This fear is rationalâ€”GINA doesn't protect life or disability insurance. So people skip testing, diseases go undetected, and preventable deaths happen."
- "Meanwhile, insurers WANT to prevent diseaseâ€”they'd love to identify MZ carriers and help them quit smokingâ€”but they can't screen without violating privacy. It's a broken system."

---

### Slide 3: The Solution

**Visual**: Fair Underwriting platform screenshot (portal showing "Your Results are Private" badge)

**Headline**: **Privacy-Protected Genetic Wellness**

**How It Works** (3-step diagram with icons):

1. **Insurer Partners with Fair Underwriting** ðŸ¤
   - Life/health insurers offer genetic testing to policyholders as wellness benefit
   - Branded co-branded portal (e.g., "Northwestern Mutual + Fair Underwriting")

2. **Customer Enrolls (Privacy Guaranteed)** âœ…
   - At-home saliva kit (mail to Quest/LabCorp)
   - Results go ONLY to customer (patent-protected privacy frameworkâ€”US 20220165374)
   - Insurer gets aggregate data only (e.g., "15% enrollment, 40 MZ carriers detected") â†’ **NO individual results**

3. **Fair Underwriting Empowers Action** ðŸ’ª
   - Genetic counseling session (licensed CGC)
   - MZ carriers get personalized action plan (smoking cessation, annual PFTs, family screening)
   - Lifestyle change support (health coaching, educational resources)

**Unique Value Proposition** (callout box):

> "The ONLY genetic testing platform where insurers can fund screening WITHOUT accessing individual customer results. Privacy + prevention, finally aligned."

**Speaker Notes**:

- "Fair Underwriting solves the catch-22. Insurers can offer genetic testing as a wellness benefitâ€”builds goodwill, attracts health-conscious customersâ€”while Fair Underwriting owns the customer relationship and results."
- "Our patent-protected framework ensures insurers CANNOT access individual results. Legally and technically impossible."
- "Customers get peace of mindâ€”test without fearâ€”and insurers get aggregate insights to prove ROI (e.g., 'Our members who tested and found MZ are 3x more likely to quit smoking')."
- "It's a win-win: customers get empowerment, insurers get prevention, Fair Underwriting gets a massive market."

---

### Slide 4: Market Opportunity

**Visual**: TAM/SAM/SOM concentric circles + bar chart showing growth

**Headline**: **$8B+ Market, Growing 15% Annually**

**Market Sizing**:

**Total Addressable Market (TAM)**: $8.2 Billion

- 250 million U.S. adults with private insurance (life, health, disability)
- Assume 25% eligible for genetic wellness programs (age 30-65, no prior genetic testing)
- 62.5 million eligible customers Ã— $130 blended price = $8.2B TAM

**Serviceable Addressable Market (SAM)**: $2.1 Billion

- Target mid-size to large insurers (100K-5M members)
- ~200 insurers in this segment, ~50M total members
- 40% penetration (wellness-forward insurers) = 20M eligible members
- 20M Ã— $105 ARPU (assuming 5% enrollment, $250/test + $30/year monitoring) = $2.1B SAM

**Serviceable Obtainable Market (SOM, Year 5)**: $75-100 Million

- 15-25 partner insurers, 5-10M total covered lives
- 5-10% enrollment rate = 250K-500K customers tested
- $250/test + 3 years Ã— $30/year monitoring = $340 LTV per customer
- Revenue: $50M-100M (assumes 50% gross margin on testing, 70% on monitoring)

**Growth Drivers** (3 icons with short descriptions):

1. **Genetic Testing Adoption** ðŸ“ˆ: 20% CAGR (Illumina, 23andMe, FDA approvals normalizing testing)
2. **Preventive Care Trend** ðŸ©º: Insurers shifting from reactive (treat disease) to proactive (prevent disease)
3. **Privacy Regulation** ðŸ”: CCPA, GDPR, genetic privacy laws â†’ demand for privacy-first solutions

**Speaker Notes**:

- "$8 billion TAM, growing at 15% annually. This is genetic testing meets preventive care meets digital healthâ€”three massive trends converging."
- "Our SAM is $2 billionâ€”focused on mid-size to large insurers with wellness programs. Think Northwestern Mutual, Cambia, regional Blues plans."
- "Year 5, we capture $75-100M of thatâ€”15-25 partner insurers, 250K-500K customers tested. That's 4-5% market share of our SAMâ€”highly achievable with first-mover advantage and patent protection."
- "And this is just AATD. Roadmap includes expansion to other genetic conditions (familial hypercholesterolemia, hereditary cancers) â†’ 5-10x TAM."

---

### Slide 5: Product

**Visual**: Screenshots of portal (desktop + mobile) showing key features

**Headline**: **End-to-End Genetic Wellness Platform**

**Product Features** (6 feature cards with screenshots):

1. **Privacy-First Testing** ðŸ”’
   - Patent-protected architecture (US 20220165374)
   - AES-256 encryption, HIPAA-compliant
   - Customer controls who sees results (delete anytime)

2. **Clinical-Grade Accuracy** ðŸ§¬
   - CLIA/CAP-certified labs (Quest, LabCorp)
   - SERPINA1 genotyping (detects MZ, ZZ, other variants)
   - 99.9% accuracy, 5-7 day turnaround

3. **Expert Genetic Counseling** ðŸ‘¨â€âš•ï¸
   - Licensed genetic counselors (ABGC-certified)
   - 30-45 min telehealth sessions
   - Personalized risk assessment + action plan

4. **Actionable Insights** ðŸ“Š
   - Easy-to-understand risk reports (visual, 8th-grade reading level)
   - MZ carrier: "2-4x COPD risk if you smoke, but preventable with healthy habits"
   - Family screening recommendations

5. **Lifestyle Change Support** ðŸ’ª
   - Smoking cessation program (12-week, evidence-based)
   - Annual health monitoring (PFT reminders, liver function tracking)
   - Health coaching (optional add-on)

6. **Partner Dashboard** ðŸ“ˆ
   - Real-time enrollment metrics (for insurers)
   - Aggregate outcomes (% MZ detected, smoking cessation rates, NPS)
   - ROI calculator (medical cost savings from early intervention)

**Technology Stack** (icon row):

- Next.js 14 (web app)
- Node.js/NestJS (API)
- PostgreSQL (data)
- AWS (infrastructure)
- Cloudflare (security/CDN)

**Speaker Notes**:

- "We're not just a genetic testâ€”we're a platform. Test is the entry point, but the value is in the counseling, action plans, and ongoing support."
- "Privacy is the foundation. Our patent allows insurers to fund testing without seeing individual resultsâ€”legally impossible for competitors to replicate without licensing our IP."
- "Clinical-grade quality. We partner with Quest and LabCorpâ€”the gold standard in lab testing. No shortcuts."
- "Genetic counselors are the secret weapon. They turn scary genetic jargon into actionable health plans. Customers love thisâ€”60+ NPS for counseling sessions."

---

### Slide 6: Business Model

**Visual**: Revenue stream waterfall chart

**Headline**: **Proven B2B2C Model with Multiple Revenue Streams**

**Revenue Streams**:

1. **Per-Test Fee** (Primary, 70% of Year 1-3 revenue)
   - Insurer pays $250-500 per customer tested
   - Blended average: $350 per test
   - Includes: genetic test + genetic counseling + 1-year portal access

2. **Annual Subscription** (Secondary, growing to 40% of Year 4-5 revenue)
   - $30-75/year per customer for ongoing monitoring
   - Includes: annual PFT reminders, updated research, family screening tools, lifestyle coaching
   - Attach rate: 20-30% of tested customers (Year 1) â†’ 40-50% (Year 5)

3. **Platform Licensing** (Future, Year 3+)
   - License Fair Underwriting platform to labs, pharma companies, employers
   - $100K-500K/year per licensee
   - White-label option (e.g., "Quest Genetic Wellness powered by Fair Underwriting")

4. **Data Licensing** (Future, Year 4+)
   - Aggregate, de-identified data for research (pharma, biotech, academia)
   - $50K-200K per dataset
   - Customer consent required, privacy-preserving (no re-identification possible)

**Unit Economics** (table):

| **Metric**               | **Year 1** | **Year 3** | **Year 5** |
| ------------------------ | ---------- | ---------- | ---------- |
| **Revenue per customer** | $250       | $320       | $400       |
| **COGS**                 | $150       | $120       | $100       |
| **Gross Margin**         | $100 (40%) | $200 (63%) | $300 (75%) |
| **CAC**                  | $600       | $400       | $300       |
| **LTV**                  | $300       | $800       | $1,500     |
| **LTV:CAC**              | 0.5x       | 2.0x       | 5.0x       |
| **Payback Period**       | 36 mo      | 18 mo      | 9 mo       |

**Speaker Notes**:

- "B2B2C modelâ€”we partner with insurers (B2B) to reach their policyholders (C). Insurers pay, customers benefit, Fair Underwriting earns recurring revenue."
- "Per-test fee is the wedgeâ€”gets us in the door. But subscriptions are the goldâ€”sticky, high-margin, growing."
- "Year 1, unit economics are underwaterâ€”LTV $300, CAC $600. But by Year 3, we're at 2x LTV:CAC (break-even), and Year 5, we're at 5x (highly profitable)."
- "The magic is in the subscription attach rate. Once customers see value (genetic counseling, lifestyle support), 40-50% renew annually. That's $30-75/year with near-zero COGSâ€”pure margin."
- "Long-term, we license the platform (Quest, pharma) and aggregate data (research). These are 80%+ margin revenue streams."

---

### Slide 7: Traction

**Visual**: Growth chart (hockey stick) + customer testimonials

**Headline**: **Pilot Traction Validates Product-Market Fit**

**Milestones Achieved** (checkmarks):

âœ… **Patent Granted** (US 20220165374, August 2024)

- Privacy-protected genetic testing framework
- 20-year exclusivity (expires 2044)
- Licensing inquiries from 3 labs, 2 insurers

âœ… **2 Pilot Partners Signed** (Q4 2024)

- Mid-size life insurers (100K-250K members each)
- 9-month pilots launched January 2025
- Combined addressable: 30,000 eligible policyholders

âœ… **1,200 Customers Enrolled** (Jan-Oct 2025)

- 8% enrollment rate (target: 5-10%)
- 950 results delivered, 250 in progress
- 45 MZ carriers detected (3.8% detection rate, in line with 2-4% population prevalence)

âœ… **Exceptional Customer Satisfaction**

- NPS: 62 overall, 68 for genetic counseling
- 87% of MZ carriers report "taking action" (smoking cessation, doctor visit, family screening)
- 94% would recommend to family/friends

âœ… **Proven ROI for Partners**

- Smoking cessation: 34% of MZ carriers who smoke quit or reduced (vs. 6% baseline quit rate)
- Medical cost savings (projected): $1,200-2,500 per MZ carrier over 5 years (early intervention prevents $5K-15K/year COPD costs)
- Partner NPS: 55 ("We're thrilled with enrollment and customer feedback")

**Revenue**:

- Q1-Q3 2025: $240K revenue ($250/test Ã— 960 tests)
- Q4 2025 (projected): $120K revenue
- FY2025 (projected): $360K total revenue
- FY2026 (projected): $1.2M revenue (3x growthâ€”4 new pilots, subscription ramp)

**Case Study Highlight** (customer testimonial box):

> "I never would have known I was MZ without Fair Underwriting. I quit smoking immediately, got a baseline PFT, and convinced my brother to get tested (he's MZ too!). This literally saved my life."
> â€” Sarah M., age 42, MZ carrier, Northwestern Mutual policyholder

**Speaker Notes**:

- "We're not a PowerPointâ€”we have real traction. 1,200 customers enrolled, 45 MZ carriers detected, 62 NPS. This is working."
- "8% enrollment rate beats our 5% target. Why? Privacy messaging resonates. Customers trust us because their insurer doesn't see their results."
- "Genetic counseling is the hero. 68 NPS for counseling sessionsâ€”customers rave about it. And 87% of MZ carriers take action. That's behavior change at scale."
- "ROI is real. 34% smoking cessation among MZ carriers vs. 6% baseline. That's a 5.7x improvement. Insurers save $1,200-2,500 per MZ carrier over 5 years by preventing COPD."
- "Partners love usâ€”NPS 55. They're already asking to expand beyond pilot. That's the signal: we've found product-market fit."

---

### Slide 8: Go-to-Market Strategy

**Visual**: 18-month roadmap with phases + partner logos

**Headline**: **Land-and-Expand Strategy with Clear Milestones**

**Phase 1: Validate (Months 1-9, Complete)** âœ…

- **Goal**: Prove concept with 2 pilot partners
- **Activities**: Close 2 pilots, enroll 1,000 customers, achieve 60+ NPS, document case studies
- **Status**: COMPLETE (exceeded targetsâ€”1,200 enrolled, 62 NPS, 2 case studies in progress)

**Phase 2: Scale Pilots (Months 10-18, In Progress)** âš™ï¸

- **Goal**: 5-7 total pilots, 5,000 customers tested
- **Activities**:
  - Close 3-5 new pilots (targeting health insurersâ€”Cambia, Highmark, regional Blues)
  - Launch subscriptions (annual monitoring $30-75/year)
  - Expand genetic counseling team (2 â†’ 5 counselors)
  - Publish case studies (partner-approved, media coverage)
- **Status**: 60% complete (pipeline: 8 active prospects, 3 LOIs signed)

**Phase 3: Expand Geographically (Months 19-30)** ðŸŒŽ

- **Goal**: National coverage (20+ partners, 50,000 customers tested)
- **Activities**:
  - Launch in Tier 2 states (CA, MAâ€”moderate regulatory complexity)
  - Partner with national insurers (e.g., Pacific Life, Guardian)
  - Platform features: mobile app, family screening portal, Spanish translation
  - Revenue: $5M-10M ARR

**Phase 4: Product Expansion (Months 31+)** ðŸš€

- **Goal**: Multi-condition genetic wellness platform
- **Roadmap**:
  - Add familial hypercholesterolemia (FH) testing (1 in 250, heart disease risk)
  - Add hereditary cancer panels (BRCA1/2, Lynch syndromeâ€”1 in 300-400)
  - Pharmacogenomics (drug-gene interactionsâ€”100% of population has actionable variants)
  - Employer channel (alongside insurers)
- **Vision**: "Fair Underwriting becomes the privacy-first genetic wellness platform for all preventive genetic testing"

**Customer Acquisition Strategy**:

1. **Insurer BD** (Primary Channel, 80% of customers)
   - Target: 5 new pilots/year (Year 1-2), 10-15/year (Year 3+)
   - Team: VP Sales + 2 BDRs (Year 2), expand to 5 reps (Year 3)
   - Conferences: LIMRA, AHIP, HLTH (exhibit, sponsor, speak)

2. **Word-of-Mouth/Referral** (Secondary Channel, 15% of customers)
   - MZ carriers refer family members (siblings, children)
   - Built-in viral loop (genetic risk is familial)
   - Incentive: $25 credit for each referred family member who tests

3. **Direct-to-Consumer** (Tertiary Channel, 5% of customers, future)
   - Website direct sales ($99-199/test)
   - Content marketing (blog, SEOâ€”"AATD testing", "MZ carrier risk")
   - Launch Year 3 (requires FDA 510(k) if LDT rule in effect)

**Speaker Notes**:

- "Clear, executable plan. Phase 1 completeâ€”pilots validated. Now we scale."
- "Phase 2 focus: 5-7 pilots by Month 18. We have 8 active prospects, 3 LOIs signedâ€”on track."
- "Geography matters. We started in favorable states (IA, NE) to prove concept. Now expanding to CA, MA (bigger markets, moderate compliance). Defer NY (too complex) until Year 3."
- "Long-term, we're not just AATD. Roadmap includes FH (1 in 250), hereditary cancers (1 in 300-400), pharmacogenomics (everyone). Fair Underwriting becomes THE privacy-first genetic wellness platform."
- "Customer acquisition is partner-ledâ€”80% through insurers. But 15% is viral (family referrals)â€”built-in growth engine."

---

### Slide 9: Competitive Landscape

**Visual**: 2Ã—2 matrix (X-axis: Privacy Protection, Y-axis: Insurance Integration)

**Headline**: **Unique Position: Privacy + Insurance, No Direct Competitors**

**Competitive Matrix**:

**Quadrant 1 (High Privacy, Low Insurance Integration)**:

- **23andMe, AncestryDNA**: DTC genetic testing, privacy-focused, but no insurance partnerships
- **Invitae, Color**: Clinical genetic testing, HIPAA-compliant, but no privacy framework for insurers
- **Weakness**: Customers pay out-of-pocket ($99-299), no insurance funding

**Quadrant 2 (High Privacy, High Insurance Integration)**:

- **Fair Underwriting** (us!) ðŸŽ¯
- Patent-protected privacy framework + insurance partnerships
- ONLY player in this quadrant

**Quadrant 3 (Low Privacy, High Insurance Integration)**:

- **Employer wellness programs** (Virgin Pulse, Livongo): Integrated with benefits, but employers see data
- **Insurer wellness programs** (UnitedHealthcare HouseCalls): Insurer-run, no privacy
- **Weakness**: Customers fear discrimination, low enrollment (2-5% for genetic screening)

**Quadrant 4 (Low Privacy, Low Insurance Integration)**:

- **Hospital genetic testing**: Doctor-ordered, medical records accessible
- **Research studies**: Institutional, consent-heavy, slow
- **Weakness**: Limited scale, not preventive/wellness-focused

**Competitive Advantages** (Fair Underwriting):

1. **Patent Moat** ðŸ°
   - US 20220165374 protects privacy framework (20-year exclusivity)
   - Competitors must license or risk infringement lawsuit

2. **First-Mover Advantage** âš¡
   - Only company with pilot partnerships + case studies + revenue
   - Incumbency (switching costs for partners)

3. **Specialization** ðŸ”¬
   - Deep expertise in AATD, MZ carriers (vs. broad genetic panels)
   - Clinical workflows, counseling scripts, educational content optimized for AATD

4. **Customer Experience** â¤ï¸
   - 62 NPS (vs. 23andMe ~40, employer wellness ~20)
   - Genetic counseling (live human support vs. automated reports)

**Potential Future Competitors** (watch list):

- **Quest/LabCorp**: Could launch competing platform, but would need to license our patent or build alternative privacy framework
- **Insurance Incumbents**: Could build in-house, but unlikely (not core competency, IP barriers)
- **Pharma/Biotech**: Could offer free testing (promotional), but different business model (drug sales, not wellness)

**Speaker Notes**:

- "Fair Underwriting occupies a unique space: privacy + insurance. No one else has both."
- "23andMe has privacy but no insurance partnershipsâ€”customers pay $99-199 out-of-pocket. Employer wellness has insurance integration but no privacyâ€”customers fear discrimination."
- "We have both. Patent-protected privacy + insurance funding. That's the magic."
- "Our patent is the moat. Competitors can't replicate without licensing our IP. Quest or LabCorp could try, but they'd need to negotiate with us first."
- "First-mover advantage is real. We have 2 pilot partners, 1,200 customers, 45 MZ carriers detected. Competitors are starting from zero."

---

### Slide 10: Team

**Visual**: Headshots + short bios for 4-6 key team members

**Headline**: **World-Class Team with Proven Track Record**

**Founders/Executives**:

**[CEO Name], CEO & Co-Founder**

- Background: 10+ years in digital health (VP Product at [prior company])
- Expertise: Product-led growth, B2B2C SaaS, FDA regulatory strategy
- Notable: Scaled [prior company] from $5M â†’ $50M ARR, exited to [acquirer]
- Education: MBA, Stanford GSB

**[CTO Name], CTO & Co-Founder**

- Background: 15+ years in healthcare technology (Principal Engineer at [prior company])
- Expertise: HIPAA-compliant systems, genetic data platforms, AWS infrastructure
- Notable: Architected platform serving 10M+ patients, 99.99% uptime
- Education: MS Computer Science, MIT

**[Chief Medical Officer Name], MD, Chief Medical Officer**

- Background: Pulmonologist, 20+ years clinical practice + 5 years digital health
- Expertise: COPD, AATD, genetic counseling, clinical guidelines (ATS/ERS)
- Notable: Published 30+ peer-reviewed papers on AATD, national speaker
- Education: MD, Johns Hopkins; Residency/Fellowship, Mayo Clinic

**[VP Sales Name], VP Sales**

- Background: 12+ years in insurance/wellness sales (Director at [prior company])
- Expertise: B2B2C partnerships, life/health insurance, pilot-to-scale playbook
- Notable: Closed 50+ insurance partnerships ($100M+ total contract value)
- Education: BA Economics, University of Pennsylvania

**[Head of Genetic Counseling Name], MS, CGC, Head of Genetic Counseling**

- Background: Licensed genetic counselor (ABGC), 10+ years in cancer + AATD counseling
- Expertise: SERPINA1/AATD, patient education, telehealth genetic counseling at scale
- Notable: Counseled 2,000+ patients, built counseling program at [prior company]
- Education: MS Genetic Counseling, University of Michigan

**Board of Directors / Advisors**:

- **[Advisor 1]**: Former Chief Medical Officer, [major insurer]â€”strategic advisor on insurance partnerships
- **[Advisor 2]**: Partner, [top VC firm]â€”investor, board member
- **[Advisor 3]**: Professor of Genetics, [university]â€”scientific advisor, AATD expert
- **[Advisor 4]**: CEO, Alpha-1 Foundationâ€”patient advocacy, awareness campaigns

**Speaker Notes**:

- "Team is everything. We've assembled world-class talent across product, engineering, clinical, sales."
- "[CEO] scaled [prior company] from $5M to $50M ARRâ€”knows how to grow B2B2C healthtech. [CTO] built platforms for 10M+ patientsâ€”can scale Fair Underwriting to millions."
- "[CMO] is a pulmonologist and AATD expertâ€”published 30+ papers, national speaker. He ensures clinical rigor and credibility with insurers."
- "[VP Sales] has closed 50+ insurance partnerships worth $100M+. She's our secret weapon for partner acquisition."
- "Advisors are strategic. [Advisor 1] was CMO at [major insurer]â€”opens doors. [Advisor 4] runs Alpha-1 Foundationâ€”patient advocacy and awareness."

---

### Slide 11: Financials

**Visual**: 5-year P&L summary (bar chart for revenue, line chart for profitability)

**Headline**: **Path to Profitability by Year 5**

**Revenue Projections** (table):

| **Metric**                  | **Year 1** | **Year 2** | **Year 3** | **Year 4** | **Year 5** |
| --------------------------- | ---------- | ---------- | ---------- | ---------- | ---------- |
| **Partner Insurers**        | 2          | 7          | 12         | 18         | 25         |
| **Customers Tested**        | 1,500      | 7,000      | 20,000     | 50,000     | 100,000    |
| **Subscription Members**    | 300        | 2,000      | 8,000      | 25,000     | 60,000     |
| **Revenue (Testing)**       | $375K      | $1.8M      | $5.0M      | $12.5M     | $25M       |
| **Revenue (Subscriptions)** | $15K       | $100K      | $400K      | $1.5M      | $4.5M      |
| **Revenue (Other)**         | $0         | $0         | $100K      | $500K      | $2M        |
| **Total Revenue**           | $390K      | $1.9M      | $5.5M      | $14.5M     | $31.5M     |
| **Gross Margin**            | 35%        | 45%        | 55%        | 65%        | 70%        |
| **Operating Expenses**      | $2.0M      | $3.5M      | $6.5M      | $11M       | $18M       |
| **EBITDA**                  | -$1.9M     | -$2.8M     | -$3.5M     | -$1.6M     | $4M        |
| **Net Income**              | -$1.9M     | -$2.9M     | -$3.6M     | -$1.8M     | $3.5M      |

**Key Assumptions**:

- Average revenue per test: $250 (Year 1) â†’ $250 (Year 5, stable)
- Subscription ARPU: $50/year (Year 1) â†’ $75/year (Year 5)
- Subscription attach rate: 20% (Year 1) â†’ 60% (Year 5)
- Gross margin expansion: 35% â†’ 70% (scale efficiencies, subscription mix)
- CAC: $600 (Year 1) â†’ $250 (Year 5, word-of-mouth, operational efficiency)

**Cash Flow & Funding** (timeline graphic):

- **Seed Round (Complete)**: $2.5M raised (Q2 2024)
  - Use: Product development, 2 pilot launches, 12-month runway
  - Investors: Healthcare angel investors, digital health fund

- **Series A (Current Raise)**: $10-15M target (Q1 2026)
  - Use: Scale to 5-7 pilots â†’ 20 pilots, hire sales/counseling teams (7 â†’ 30 employees), expand to Tier 2 states, platform features
  - Runway: 24-30 months (to breakeven or Series B)

- **Series B (Future)**: $20-30M projected (Q3 2027)
  - Use: National expansion (50+ partners), product expansion (FH, hereditary cancers), enterprise sales team, Series C/IPO prep
  - Milestone: $15M+ ARR, positive unit economics, clear path to $100M ARR

**Speaker Notes**:

- "Capital-efficient model. We're raising $10-15M Series A to scale from 2 pilots to 20 pilots, 1,500 customers to 50,000 customers."
- "Burn is manageableâ€”$2M/year in Year 1, $3.5M/year in Year 3. This isn't a burn-$50M-to-find-product-market-fit story. We've found it. Now we scale."
- "Profitability in Year 5. $31.5M revenue, $3.5M net income, 11% net margin. That's a VC-backable outcome."
- "Gross margin expansion is the keyâ€”35% Year 1 (testing-heavy, high COGS) to 70% Year 5 (subscription mix, negotiated lab discounts). By Year 5, 60% of customers are subscribers at $75/year with near-zero COGS."
- "Series A funds us to Series B or breakeven. Conservative scenario: 24-month runway. Optimistic: hit $5M ARR by Month 18, raise Series B from position of strength."

---

### Slide 12: Use of Funds

**Visual**: Pie chart showing allocation of $12M Series A (midpoint of $10-15M range)

**Headline**: **$12M Series A Allocation: Scale Pilots, Build Team, Expand Product**

**Budget Breakdown**:

1. **Sales & Marketing** (35%, $4.2M)
   - Hire VP Sales + 4 BDRs ($800K/year salaries + commissions)
   - Conferences & events (LIMRA, AHIP, HLTHâ€”$300K/year)
   - Marketing campaigns (partner co-marketing, content, PRâ€”$400K/year)
   - Pilot incentives (discounted pricing for first 10 pilotsâ€”$500K total)
   - Total: $4.2M over 24 months

2. **Product & Engineering** (25%, $3M)
   - Hire 3 engineers (platform features, mobile app, integrationsâ€”$600K/year)
   - Hire 1 product manager ($200K/year)
   - Hire 1 designer ($150K/year)
   - Infrastructure (AWS, Cloudflare, toolsâ€”$200K/year)
   - Total: $3M over 24 months

3. **Clinical Operations** (20%, $2.4M)
   - Hire 3 genetic counselors ($450K/year salaries + benefits)
   - Genetic counseling platform (telehealth softwareâ€”$50K/year)
   - Lab fees (5,000 tests @ $100/test = $500K/year)
   - Medical director consulting ($100K/year)
   - Total: $2.4M over 24 months

4. **Regulatory & Legal** (10%, $1.2M)
   - FDA 510(k) application (if LDT rule requiresâ€”$300K)
   - State licensing (CA, MA, othersâ€”$200K)
   - Legal fees (contracts, IP, complianceâ€”$200K/year)
   - Compliance audits (HIPAA, SOC 2â€”$100K/year)
   - Total: $1.2M over 24 months

5. **General & Administrative** (10%, $1.2M)
   - Hire CFO ($250K/year)
   - Hire 2 operations staff ($200K/year)
   - Office/overhead ($100K/year)
   - Insurance (D&O, E&O, cyberâ€”$150K/year)
   - Total: $1.2M over 24 months

**Milestones Funded by Series A**:

- âœ… Scale from 2 â†’ 20 pilot partners (Month 6-24)
- âœ… Grow from 1,500 â†’ 50,000 customers tested (Month 6-24)
- âœ… Launch subscriptions, achieve 40% attach rate (Month 12)
- âœ… Expand to CA, MA, 5 other Tier 2 states (Month 12-18)
- âœ… Build mobile app + family screening portal (Month 9-15)
- âœ… Achieve $5M ARR (Month 18-24)
- âœ… Raise Series B or reach breakeven (Month 24+)

**Speaker Notes**:

- "$12M funds 24 months to scale. Biggest allocation: sales & marketing (35%)â€”because partner acquisition is the bottleneck."
- "We're hiring a sales team: VP Sales + 4 BDRs to close 10-15 new pilots/year. That's $4.2M, but it unlocks $20M+ in revenue."
- "Product & engineering gets 25%â€”we need mobile app, family screening, API integrations to scale. 3 engineers + PM + designer."
- "Clinical operations is 20%â€”3 genetic counselors to handle 50,000 tests. That's manageable with our group counseling and automation."
- "Regulatory/legal is 10%â€”FDA 510(k) if needed ($300K), state licensing ($200K), contracts. This de-risks the business."
- "By Month 24, we're at $5M ARR, 20 pilots, 50K customersâ€”ready for Series B or breakeven."

---

### Slide 13: Why Now?

**Visual**: Timeline showing 3 converging trends (arrows merging)

**Headline**: **Perfect Timing: 3 Mega-Trends Converge**

**Trend 1: Genetic Testing Goes Mainstream** ðŸ§¬

- **2013**: 23andMe launches DTC testing ($99)
- **2017**: FDA approves 23andMe health reports (genetic risk for 10 conditions)
- **2020**: COVID-19 normalizes at-home testing (hundreds of millions of people mail samples)
- **2023**: Illumina launches $200 whole genome sequencing
- **2024**: 100M+ Americans have taken genetic test (23andMe, AncestryDNA, clinical)
- **Impact**: Public comfortable with genetic testing, ready for next generation (preventive, actionable)

**Trend 2: Privacy Concerns Explode** ðŸ”

- **2018**: GDPR (Europe), CCPA (California) passâ€”privacy is mainstream concern
- **2019**: 23andMe data breach (concerns about genetic data security)
- **2021**: Genetic Discrimination Act proposals in 15+ states (expand GINA to life/disability insurance)
- **2023**: Public polls: 72% fear genetic discrimination by insurers
- **2024**: Fair Underwriting patents privacy-protected framework (US 20220165374)
- **Impact**: Market demand for privacy-first genetic testing at all-time high

**Trend 3: Insurers Embrace Preventive Care** ðŸ©º

- **2015**: ACA expands preventive care coverage (annual wellness visits, screenings)
- **2018**: Value-based care models grow (insurers rewarded for outcomes, not volume)
- **2020**: COVID-19 proves preventive care ROI (vaccines save lives + money)
- **2022**: Insurers launch wellness programs (Virgin Pulse, Livongo acquisitions)
- **2024**: Life insurers offer genetic testing pilots (but struggle with privacy â†’ **Fair Underwriting solves this**)
- **Impact**: Insurers actively seeking genetic wellness solutions, budgets allocated

**Why Fair Underwriting Wins Now**:

- âœ… **Genetic testing is normalized** â†’ customers willing to test
- âœ… **Privacy is a priority** â†’ customers demand protection â†’ Fair Underwriting's patent is the solution
- âœ… **Insurers have budgets** â†’ wellness programs are funded â†’ Fair Underwriting is the vendor of choice

**Timing Risk if We Wait**:

- âŒ **Competitors emerge**: Quest, LabCorp, 23andMe could launch competing platforms (we lose first-mover advantage)
- âŒ **Regulatory tightening**: FDA could regulate LDTs more strictly (harder to launch)
- âŒ **Privacy backlash**: Another genetic data breach could spook customers (market freezes)

**Speaker Notes**:

- "Timing is everything. Fair Underwriting exists at the intersection of three massive trends: genetic testing, privacy, and preventive care."
- "Genetic testing is mainstreamâ€”100M+ Americans tested. COVID normalized at-home testing. Illumina offers $200 whole genome sequencing. The tech is ready."
- "Privacy concerns are at an all-time highâ€”72% of Americans fear genetic discrimination. GDPR, CCPA, genetic discrimination bills in 15 states. Our patent solves this."
- "Insurers are readyâ€”they're launching wellness programs, budgets are allocated. They WANT genetic screening but didn't have a privacy-first solution. Until now."
- "If we wait, we lose. Quest or 23andMe could copy us (though they'd need our patent license). FDA could tighten regulations. Another data breach could freeze the market."
- "The window is NOW. 2025-2027 is the golden era for genetic wellness. Fair Underwriting is perfectly positioned."

---

### Slide 14: Investment Highlights

**Visual**: 5 key takeaways (icon + short text)

**Headline**: **Why Invest in Fair Underwriting?**

**1. Massive Market, Clear Need** ðŸ“ˆ

- $8B+ TAM, 15% CAGR
- 100,000+ Americans with AATD, 90% undiagnosed
- 2.5M+ MZ carriers in U.S., most don't know
- Insurers spend $5K-15K/year per COPD patient â†’ prevention is cheaper

**2. Proven Product-Market Fit** âœ…

- 1,200 customers enrolled, 62 NPS
- 2 pilot partners, 3 LOIs signed for new pilots
- 87% of MZ carriers take action (smoking cessation, doctor visit)
- 34% smoking cessation rate (vs. 6% baseline)
- Partner NPS: 55 ("We're thrilled")

**3. Patent-Protected Moat** ðŸ°

- US 20220165374 (granted August 2024, expires 2044)
- Privacy-protected genetic testing framework (insurer can't access individual results)
- Licensing inquiries from 3 labs, 2 insurers
- Defensible competitive position

**4. Capital-Efficient, Scalable Model** ðŸ’°

- B2B2C (insurers pay, Fair Underwriting owns customer relationship)
- Unit economics: LTV $300 (Year 1) â†’ $1,500 (Year 5), LTV:CAC 0.5x â†’ 5x
- Gross margin: 35% â†’ 70% (subscription mix)
- Profitability: Year 5 ($31.5M revenue, $3.5M net income, 11% margin)
- Modest capital needs: $10-15M Series A â†’ $20-30M Series B â†’ breakeven/IPO

**5. Exceptional Team with Proven Track Record** ðŸ‘¥

- CEO scaled prior company $5M â†’ $50M ARR
- CTO built platforms serving 10M+ patients
- CMO is national AATD expert (30+ publications)
- VP Sales closed 50+ insurance partnerships ($100M+ TCV)
- Advisors: former insurer CMO, Alpha-1 Foundation CEO, top VC partner

**Speaker Notes**:

- "Five reasons to invest: massive market, proven traction, patent moat, scalable economics, world-class team."
- "Market is $8B+, growing 15%/year. AATD affects 100K+ Americans, 90% undiagnosed. We're solving a real problem."
- "Product-market fit is proven. 1,200 customers, 62 NPS, 87% of MZ carriers take action. Partners love usâ€”NPS 55, asking to expand pilots."
- "Patent is the moat. 20-year exclusivity. Competitors can't replicate without licensing our IP."
- "Economics work. By Year 5, we're at 5x LTV:CAC, 70% gross margin, 11% net margin. This is a venture-scale outcome."
- "Team is exceptional. We've done this beforeâ€”scaled B2B2C healthtech, closed insurance deals, built HIPAA platforms. We know how to win."

---

### Slide 15: The Ask

**Visual**: Funding target + use of funds summary

**Headline**: **Join Us in Building the Future of Genetic Wellness**

**Series A Fundraise**:

- **Target**: $10-15M
- **Valuation**: $40-50M post-money (10-12x revenue multiple on Year 2 ARR of $3.5M-4M)
- **Lead Investor**: Seeking $5-8M lead
- **Timeline**: Close Q1 2026 (Jan-Mar)

**What This Unlocks**:

- ðŸ“Š Scale from 2 â†’ 20 pilot partners
- ðŸ§¬ Grow from 1,500 â†’ 50,000 customers tested
- ðŸŒ Expand to CA, MA, national coverage
- ðŸ“± Launch mobile app + family screening portal
- ðŸ’° Achieve $5M ARR by Month 18-24
- ðŸš€ Position for Series B or breakeven

**Target Investors**:

- Healthcare/digital health VCs (prior investments in telehealth, genomics, insurance tech)
- Impact investors (lives saved, preventable disease mission)
- Strategic investors (insurers, labs, pharmaâ€”potential partners or acquirers)

**Next Steps**:

1. **Follow-up meeting** (deep dive on financials, product roadmap, partnership pipeline)
2. **Due diligence** (customer calls, partner references, technical review)
3. **Term sheet** (within 2-4 weeks of deep dive)
4. **Close** (Q1 2026)

**Contact**:

- **[CEO Name]**, CEO
- **[Email]**
- **[Phone]**
- **[Website: fairunderwriting.com]**

**Closing Statement** (speaker notes):

> "Fair Underwriting is solving one of healthcare's biggest problems: genetic testing that's preventive, actionable, and privacy-protected. We've proven the model worksâ€”1,200 customers, 62 NPS, 2 pilot partners asking to expand. Now we need capital to scale from 2 pilots to 20, from 1,500 customers to 50,000. Join us in building the future of genetic wellness. Let's save lives and build a unicorn together."

---

## Appendix (Backup Slides)

### Appendix A: Detailed Financials (5-Year Model)

[Full P&L, cash flow, balance sheetâ€”copy from FINANCIAL_MODEL_DETAILED.md]

---

### Appendix B: Regulatory Deep Dive

[HIPAA, GINA, FDA, state lawsâ€”copy from REGULATORY_COMPLIANCE_GUIDE.md]

---

### Appendix C: Clinical Evidence

[16+ peer-reviewed studies on MZ risk, interventionsâ€”copy from CLINICAL_EVIDENCE_DATABASE.md]

---

### Appendix D: Partnership Agreement Summary

[MSA, BAA, DPA termsâ€”copy from PARTNERSHIP_AGREEMENT_TEMPLATES.md]

---

### Appendix E: Customer Case Studies

**Case Study 1: Sarah M., Age 42, MZ Carrier**

- **Background**: Northwestern Mutual policyholder, smoker (1 pack/day, 20 years)
- **Journey**: Enrolled in Fair Underwriting pilot (January 2025), tested MZ, genetic counseling session (February 2025)
- **Action**: Quit smoking (using varenicline + support group), baseline PFT (normal), convinced brother to test (also MZ)
- **Outcome**: Reduced COPD risk 58% (smoking cessation), family cascade screening (brother now in counseling)
- **Quote**: "I never would have known I was MZ without Fair Underwriting. This literally saved my life."

**Case Study 2: John D., Age 55, ZZ Carrier**

- **Background**: Cambia Health policyholder, former smoker (quit 10 years ago), mild shortness of breath
- **Journey**: Enrolled in Fair Underwriting pilot (March 2025), tested ZZ, urgent genetic counseling (March 2025)
- **Action**: Pulmonologist referral, PFTs (moderate obstruction, FEV1 62%), started augmentation therapy (Prolastin-C IV weekly), annual PFT monitoring
- **Outcome**: Prevented progression (augmentation therapy slows decline 34%), early diagnosis (vs. typical 5-7 year diagnostic delay)
- **Quote**: "I thought it was just age-related shortness of breath. Finding out I'm ZZ and starting treatment early has been life-changing."

---

### Appendix F: Technology Architecture Diagram

[Platform architecture, data flows, security controlsâ€”technical deep dive for CTO/engineering review]

---

## Presentation Tips

**Delivery** (10-min pitch):

- **Slides 1-3** (2 min): Problem â†’ Solution â†’ hook investor interest
- **Slides 4-7** (3 min): Market, Product, Business Model, Traction â†’ prove opportunity + execution
- **Slides 8-10** (2 min): Go-to-Market, Competitive Landscape, Team â†’ de-risk investment
- **Slides 11-13** (2 min): Financials, Use of Funds, Why Now â†’ show path to returns
- **Slides 14-15** (1 min): Investment Highlights, The Ask â†’ close strong

**Q&A Preparation** (anticipate these questions):

1. **"How defensible is your patent? Can Quest or LabCorp work around it?"**
   - Answer: Patent covers the core innovation (insurer-funded testing without individual result access). Workarounds would be materially different (e.g., customer pays, insurer doesn't fund â†’ worse value prop). We've consulted patent attorneysâ€”strong IP position. If Quest/LabCorp want to enter, they'll license from us (revenue opportunity).

2. **"What if insurers build this in-house?"**
   - Answer: Unlikelyâ€”not core competency (insurers are risk managers, not genetic testing platforms). Also, our patent protects the framework. They'd need to license or build inferior alternative. Easier to partner with us.

3. **"Why will customers trust Fair Underwriting with genetic data?"**
   - Answer: Transparency + third-party validation. Privacy policy is clear ("your insurer will NOT see your results"). HIPAA-compliant, SOC 2 certified. Customer testimonials (62 NPS). Also, we're not the insurerâ€”we're the neutral third party protecting customers FROM insurers.

4. **"What if FDA requires 510(k) for SERPINA1 testing?"**
   - Answer: We've budgeted $300K for 510(k) (included in Use of Funds). Timeline: 6-12 months. Mitigation: Labs (Quest, LabCorp) may already have 510(k) for SERPINA1â€”we rely on their certification. If Fair Underwriting must sponsor, we will (cost is manageable, de-risks business long-term).

5. **"How do you prevent adverse selection (only high-risk customers test)?"**
   - Answer: Insurer offers to ALL policyholders (broad population), not just high-risk. Enrollment is 5-10%â€”includes healthy people curious about genetics. Also, we're identifying MZ carriers BEFORE they're symptomatic (not adverse selection, it's early detection). Insurers benefit from prevention.

6. **"Why won't 23andMe or Invitae compete?"**
   - Answer: Different business models. 23andMe is DTC (customer pays $99-199, no insurance integration). Invitae is clinical (doctor-ordered, medical necessity). Fair Underwriting is B2B2C wellness (insurer pays, preventive). Also, our patent protects privacy frameworkâ€”they can't replicate without licensing.

7. **"What's your customer acquisition cost (CAC) really going to be at scale?"**
   - Answer: Year 1 CAC is $600 (high partner acquisition cost spread over small customer base). By Year 5, CAC drops to $250-300 (partner acquisition cost spread over larger base, word-of-mouth referrals, operational efficiency). We track this closelyâ€”it's the key to profitability.

8. **"How do you retain customers (low churn)?"**
   - Answer: Subscriptions. One-time test has zero retention, but annual monitoring ($30-75/year) creates recurring relationship. 40-50% attach rate by Year 5. Also, MZ carriers are highly engaged (they WANT annual PFT reminders, updated research)â€”low churn (<10%/year).

---

**Document Owner**: CEO + CFO + Board of Directors
**Review Frequency**: Update quarterly (metrics, traction, financials)
**Last Updated**: November 7, 2025
**Next Fundraise**: Series A close target Q1 2026
